

Objection Deadline: December 6, 2022 at 12:00 p.m. (Prevailing Eastern Time)

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

**PURDUE PHARMA L.P., *et al.*,

Debtors. ¹**

Chapter 11

Case No. 19-23649

(Jointly Administered)

**NOTICE OF THIRTY-SEVENTH MONTHLY STATEMENT OF
SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
FOR COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT
OF EXPENSES INCURRED AS SPECIAL COUNSEL TO THE DEBTORS
FOR THE PERIOD FROM OCTOBER 1, 2022 THROUGH OCTOBER 31, 2022**

Name of Applicant:	Skadden, Arps, Slate, Meagher & Flom LLP
Authorized to Provide Services to:	Purdue Pharma L.P., <i>et al.</i>
Date of Retention:	November 25, 2019, <i>nunc pro tunc</i> to September 15, 2019
Period for Which Compensation and Expense Reimbursement is Sought:	October 1, 2022 through October 31, 2022
Amount of Compensation Requested:	\$494,560.35
Less 20% Holdback:	\$98,912.07
Net of Holdback:	\$395,648.28
Amount of Expense Reimbursement Requested:	\$ 75,000.00
Total Compensation (Net of Holdback) and Expense Reimbursement Requested:	\$470,648.28

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P., Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

In accordance with the Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals, dated November 21, 2019 [Docket No. 529] (the “**Interim Compensation Order**”),² Skadden, Arps, Slate, Meagher & Flom LLP (“**Skadden**”) hereby submits this Thirty-Seventh monthly statement (the “**Thirty-Seventh Monthly Statement**”), seeking compensation for services rendered and reimbursement of expenses incurred as special counsel to the Debtors, for the period from October 1, 2022 through October 31, 2022 (the “**Thirty-Seventh Monthly Period**”). By this Thirty-Seventh Monthly Statement, and after taking into account certain voluntary discounts and reductions,³ Skadden seeks payment in the amount of \$470,648.28 which comprises (i) 80% of the total amount of compensation sought for actual and necessary services rendered during the Thirty-Seventh Monthly Period and (ii) reimbursement of 100% of actual and necessary expenses incurred in connection with such services.

SERVICES RENDERED AND EXPENSES INCURRED

1. Attached hereto as **Exhibit A** is a summary of Skadden professionals by individual, setting forth the (a) name and title of each individual who provided services for the Thirty-Seventh Monthly Period, (b) aggregate hours spent by each individual, (c) hourly billing rate for each such individual at Skadden’s then-current billing rates, (d) amount of fees earned by each Skadden professional, and (e) year of bar admission for each attorney. The blended hourly

² Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Interim Compensation Order.

³ In addition to the volume discount, the total amount sought for fees and expenses (\$569,560.35) reflects voluntary reductions for this period of \$41,957.00 in fees and \$1,704.65 in expenses, for an overall voluntary reduction of 6.53%. Skadden reserves the right to request these amounts.

billing rate of Skadden timekeepers during the Thirty-Seventh Monthly Period is approximately \$1,179.72.⁴

2. Attached hereto as **Exhibit B** is a summary of the services rendered and compensation sought, by project category, for the Thirty-Seventh Monthly Period.

3. Attached hereto as **Exhibit C** is a summary of expenses incurred and reimbursement sought, by expense type, for the Thirty-Seventh Monthly Period.

4. Attached hereto as **Exhibit D** is itemized time records of Skadden professionals for the Thirty-Seventh Monthly Period and summary materials related thereto.

NOTICE AND OBJECTION PROCEDURES

5. Notice of this Thirty-Seventh Monthly Statement shall be given by hand or overnight delivery upon the following parties (the “**Application Recipients**”): (i) Purdue Pharma L.P., 201 Tresser Blvd, Stamford, CT 06901, Attn.: Terrence Ronan, Email: Terrence.Ronan@pharma.com; (ii) counsel to the Debtors, Davis Polk & Wardwell LLP, 450 Lexington Avenue, New York, New York 10017, Attn.: Christopher Robertson and Dylan Consla, Email: christopher.robertson@davispolk.com, dylan.consla@davispolk.com; (iii) counsel to the Committee: (a) Akin Gump Strauss Hauer & Feld LLP, One Bryant Park, Bank of America Tower, New York, New York 10036-6745, Attn.: Arik Preis and Sara L. Brauner, Email: apreis@akingump.com and sbrauner@akingump.com; and (b) Bayard, P.A., 600 N. King Street, Suite 400, Wilmington, DE 19801, Attn.: Justin R. Alberto and Daniel N. Brogan, Email: jalberto@bayardlaw.com and dbrogan@bayardlaw.com; and (iv) the Office of the United States Trustee, U.S. Federal Office Building, 201 Varick Street, Suite 1006, New

⁴ The blended rate is comprised of all Skadden timekeepers who provided services during the Thirty-Seventh Monthly Period.

York, New York 10014, Attn.: Paul K. Schwartzberg, Email: Paul.Schwartzberg@usdoj.gov.
(collectively, the “**Notice Parties**”).

6. Objections to this Thirty-Seventh Monthly Statement, if any, must be served upon the Notice Parties, and by email, hand, or overnight delivery upon Skadden, Arps, Slate, Meagher & Flom LLP, 1440 New York Avenue NW, Washington, D.C. 20005, Attn.: Jennifer Bragg, Email: Jennifer.Bragg@skadden.com, 155 North Wacker Drive, Chicago, Illinois 60606, Attn.: Patrick Fitzgerald, Email: Patrick.Fitzgerald@skadden.com, 300 South Grand Avenue, Suite 3400, Los Angeles, California 90071, Attn.: Van Durrer, Email: Van.Durrer@skadden.com, and 525 University Avenue, Palo Alto, California, 94301, Attn.: Jennifer Madden, Email: Jennifer.Madden@skadden.com no later than December 1, 2022 at 12:00 p.m. (Prevailing Eastern Time) (the “**Objection Deadline**”), setting forth the nature of the objection and the specific amount of fees or expenses at issue.

7. If no objections to this Thirty-Seventh Monthly Statement are received by the Objection Deadline, the Debtors shall promptly pay Skadden 80% of the fees and 100% of the expenses identified in this Thirty-Seventh Monthly Statement.

8. To the extent that an objection to this Thirty-Seventh Monthly Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Thirty-Seventh Monthly Statement to which the objection is directed and promptly pay the remainder of the fees and expenses in the percentages set forth above. To the extent such objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing.

Dated: November 22, 2022

SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

/s/ Van C. Durrer II

Van C. Durrer II
300 South Grand Avenue
Los Angeles, CA 90071
Telephone: (213) 687-5000
Fax: (213) 687-5600

– and –

Patrick Fitzgerald
155 North Wacker Drive
Chicago, Illinois 60606-1720
Telephone: (312) 407-0700
Fax: (312) 407-0411

– and –

Jennifer L. Bragg
1440 New York Avenue, N.W.
Washington, D.C. 20005
Telephone: (202) 371-7000
Fax: (202) 393-5760

*Special Counsel to Debtors
and Debtors in Possession*

EXHIBIT A
SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
PROFESSIONAL PERSON SUMMARY
OCTOBER 1, 2022 – OCTOBER 31, 2022

<u>NAME</u>	<u>YEAR OF ADMISSION</u>	<u>RATE</u>	<u>HOURS</u>	<u>AMOUNT</u>
<u>PARTNER</u>				
Jennifer L. Bragg	1996	1,650.00	56.10	\$ 92,565.00
Avia M. Dunn	2008	1,325.00	20.70	27,427.50
Patrick Fitzgerald	1986	1,850.00	10.20	18,870.00
Maya P. Florence	2004	1,510.00	87.70	132,427.00
Marie L. Gibson	1997	1,650.00	15.60	25,740.00
William (Bill) McConagha	1993	1,495.00	14.30	21,378.50
William Ridgway	2006	1,495.00	5.40	8,073.00
Resa K. Schlossberg	2005	1,495.00	3.60	5,382.00
TOTAL PARTNER			213.60	\$ 331,863.00
<u>ASSOCIATE</u>				
Pamela I. Amaechi	2019	865.00	14.50	\$ 12,542.50
William A. Bejan	2018	985.00	28.70	28,269.50
Amanda H. Chan	2019	985.00	28.60	28,171.00
Taylor L. Davis	2022	600.00	39.80	23,880.00
Barri Dean	2019	985.00	21.10	20,783.50
Lucy Dicks-Mireaux	2020	735.00	35.50	26,092.50
A. Caroline M. Frizzo	2011	1,125.00	13.90	15,637.50
Emily Hellman	2017	1,090.00	8.90	9,701.00
Jennifer Madden	2010	1,180.00	10.20	12,036.00
William S. O'Hare	2013	1,180.00	0.90	1,062.00
Dorielle Obanor	2017	1,090.00	6.10	6,649.00
Yogini P. Patel	2018	985.00	9.10	8,963.50
Brianna M. van Kan	2016	1,125.00	2.40	2,700.00
Catherine Yuh	2020	865.00	14.90	12,888.50
TOTAL ASSOCIATE			234.60	\$ 209,376.50
<u>PARAPROFESSIONALS</u>				
Mark D. Campana	N/A	470.00	2.30	\$ 1,081.00
William R. Fieberg	N/A	470.00	2.70	1,269.00

Michael J. Hohmann	N/A	470.00	2.80	1,316.00
Rachel Redman	N/A	470.00	5.50	2,585.00
Alfred M. Raucci	N/A	470.00	4.30	2,021.00
TOTAL PARAPROFESSIONALS			17.60	\$ 8,272.00
TOTAL			465.80	\$ 549,511.50
VOLUME DISCOUNT				\$ 54,951.15
TOTAL FEES				\$ 494,560.35
BLENDED HOURLY RATE \$1,179.72				

EXHIBIT B
SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
COMPENSATION BY PROJECT CATEGORY
(OCTOBER 1, 2022 – OCTOBER 31, 2022)

Project Category	Total Hours	Total Fees
Bankruptcy Emergence Process	12.70	\$ 17,875.50
Corporate M&A	47.40	57,770.00
Corporate/Transactional Advice	3.30	3,250.50
DOJ	152.20	197,585.00
General Advice	208.60	229,836.00
Project Catalyst	4.60	7,218.00
Retention/Fee Matter	31.50	33,391.50
Various Texas Actions	5.50	2,585.00
TOTAL	465.80	\$ 549,511.50
VOLUME DISCOUNT		\$ 54,951.15
TOTAL FEES		\$ 494,560.35

EXHIBIT C
SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
EXPENSE SUMMARY
(OCTOBER 1, 2022 – OCTOBER 31, 2022)

Expense Category	Total Expenses
Secondment of Skadden Attorney	\$65,000.00
Secondment of Skadden Paraprofessional	10,000.00
TOTAL	\$75,000.00

EXHIBIT D

TIME DETAIL

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

Purdue Pharma L.P.
Bankruptcy Emergence Process

Bill Date: 11/14/22
Bill Number: 1917959

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	10/14/22	0.60	REVIEW AND EDIT LICENSING DOCUMENTS (0.6).
		0.60	
DUNN AM	10/01/22	0.20	REVIEW CORRESPONDENCE RE STATE LICENSING ISSUES (0.2).
DUNN AM	10/05/22	1.00	PARTICIPATE ON STANDING LICENSING CALL (0.4); REVIEW MATERIALS RE: SAME (0.6).
DUNN AM	10/12/22	0.40	REVIEW CORRESPONDENCE RE STATE LICENSING QUESTIONS (0.4).
DUNN AM	10/12/22	0.80	PARTICIPATE ON STANDING LICENSING CALL (0.8).
DUNN AM	10/26/22	0.30	REVIEW AND RESPOND TO QUESTIONS RE: STATE LICENSING RESPONSES (0.3).
DUNN AM	10/26/22	0.70	PARTICIPATE ON STANDING STATE LICENSING CALL (0.7).
DUNN AM	10/27/22	0.40	REVIEW AND RESPOND TO QUESTIONS RE: STATE LICENSING RESPONSES (0.4).
		3.80	
FLORENCE MP	10/10/22	0.20	CORRESPOND WITH CLIENT RE: STATE LICENSE APPLICATION (0.2).
FLORENCE MP	10/11/22	1.00	CORRESPOND WITH J. BRAGG AND CLIENT RE: STATE LICENSING (1.0).
FLORENCE MP	10/12/22	0.50	PARTICIPATE IN WEEKLY STATE LICENSING CALL (0.3); CORRESPOND WITH CLIENT RE: STATE LICENSING QUESTION (0.2).
FLORENCE MP	10/14/22	0.90	CORRESPOND WITH CLIENT AND CO-COUNSEL RE: STATE LICENSE APPLICATION (0.2); PARTICIPATE IN CALL WITH CLIENT AND CONSULTANT RE: SAME (0.3); REVIEW AND EDIT DRAFT DISCIPLINARY STATEMENT (0.4).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	10/17/22	0.60	CORRESPOND WITH CLIENT RE: STATE LICENSE APPLICATIONS (0.3); REVIEW AND COMMENT ON DRAFT CONSULTANT ENGAGEMENT LETTER (0.3).
FLORENCE MP	10/18/22	0.50	CORRESPOND WITH CLIENT AND SKADDEN TEAM RE: DRAFT ENGAGEMENT LETTER (0.5).
FLORENCE MP	10/24/22	0.20	CORRESPOND WITH CONSULTANT RE: DRAFT SOW (0.2).
FLORENCE MP	10/25/22	1.30	CORRESPOND WITH CLIENT RE: CHANGE OF ADDRESS PROCESS (0.7); CONFER WITH CO-COUNSEL RE: SAME (0.3); CORRESPOND WITH CONSULTANT RE: SAME (0.3).
FLORENCE MP	10/26/22	0.60	CORRESPOND WITH CLIENT AND CO-COUNSEL RE: STATE LICENSE FILINGS (0.6).
FLORENCE MP	10/27/22	0.40	CORRESPOND WITH CLIENT RE: STATE LICENSING APPLICATIONS (0.4).
FLORENCE MP	10/31/22	0.80	PARTICIPATE IN CALL RE: GOVERNMENT CONTRACTS (0.8).
		7.00	
Total Partner		11.40	
DEAN B	10/05/22	0.60	PARTICIPATE ON WEEKLY STATE LICENSING CALL (0.6).
DEAN B	10/12/22	0.20	PARTICIPATE ON WEEKLY STATE LICENSING CALL (0.2).
DEAN B	10/26/22	0.50	PARTICIPATE ON WEEKLY STATE LICENSING CALL (0.5).
		1.30	
Total Associate		1.30	
MATTER TOTAL		<u>12.70</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Corporate M&ABill Date: 11/14/22
Bill Number: 1917962

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	10/03/22	0.80	CONFER WITH CLIENT REGARDING NEW TRANSACTION (0.8).
BRAGG JL	10/14/22	0.80	CONFER WITH CLIENT RE: TRANSACTION (0.3); REVIEW MATERIALS (0.5).
		1.60	
GIBSON ML	10/03/22	1.00	CALL WITH CLIENT AND INTERNAL TEAM RE: NEW PROJECT (1.0).
GIBSON ML	10/13/22	0.80	CONFER WITH TEAM RE: KICK OFF OF PROJECT WITH CLIENT AND INTERNAL TEAM (0.8).
GIBSON ML	10/14/22	3.30	REVIEW MATERIALS SENT BY CLIENT (0.3); MULTIPLE CORRESPONDENCE RE: NEXT STEPS (1.0); COMMENT ON DRAFTS OF DECK (1.0); COMMUNICATIONS RE: DATA ROOM (1.0).
GIBSON ML	10/16/22	0.40	REVIEW AND COMMENT ON DUE DILIGENCE REQUEST LIST (0.4).
GIBSON ML	10/17/22	2.00	CALL WITH CLIENT (0.5); REVIEW AND COMMENT ON TIMELINE (0.5); FOLLOW UP CALL (0.5); MULTIPLE CORRESPONDENCE (0.5).
GIBSON ML	10/18/22	0.30	MULTIPLE CORRESPONDENCE WITH WORKING GROUP COORDINATING NEXT STEPS (0.3).
GIBSON ML	10/20/22	0.70	REVIEW AND COMMENT ON REGULATORY FORM (0.7).
GIBSON ML	10/21/22	1.60	CONFERENCE CALL WITH CLIENT AND CONSULTANT (0.6); FOLLOW UP CALL WITH CLIENT (0.5); FOLLOW UP ON NEXT STEPS WITH INTERNAL TEAM AND RELATED CORRESPONDENCE (0.5).
GIBSON ML	10/24/22	0.70	REVIEW IP MATERIALS TO PREPARE FOR CALL (0.7).
GIBSON ML	10/25/22	1.90	PRE CALL WITH CO-COUNSEL (0.2); CALL WITH CLIENT (1.5); FOLLOW UP WITH ASSOCIATES (0.2).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

GIBSON ML	10/31/22	0.70	CORRESPONDENCE WITH WORKING GROUP (0.7).
-----------	----------	------	--

13.40

SCHLOSSBERG RK	10/17/22	0.20	CONFER WITH INTERNAL SKADDEN COLLEAGUES RE: TRANSACTION (0.2).
----------------	----------	------	--

SCHLOSSBERG RK	10/18/22	0.20	CONFER WITH INTERNAL SKADDEN COLLEAGUES RE: TRANSACTION (0.2).
----------------	----------	------	--

SCHLOSSBERG RK	10/21/22	0.50	REVIEW AND ANALYZE TRANSACTION RELATED DOCUMENTS (0.5).
----------------	----------	------	---

SCHLOSSBERG RK	10/21/22	0.20	CONFER WITH CLIENT (0.2).
----------------	----------	------	---------------------------

SCHLOSSBERG RK	10/21/22	0.10	CONFER WITH INTERNAL SKADDEN COLLEAGUES RE: TRANSACTION (0.1).
----------------	----------	------	--

1.20**Total Partner 16.20**

FRIZZO A	10/13/22	0.20	DISCUSS TRANSACTION WITH M. GIBSON (0.2).
----------	----------	------	---

FRIZZO A	10/14/22	0.50	DISCUSS VDR ORGANIZATION AND OTHER MATTER WITH INTERNAL TEAM (0.5).
----------	----------	------	---

FRIZZO A	10/15/22	0.20	COORDINATE TRANSACTION LIST (0.2).
----------	----------	------	------------------------------------

FRIZZO A	10/16/22	1.80	REVIEW / REVISE LEGAL REQUEST LIST (1.8).
----------	----------	------	---

FRIZZO A	10/17/22	4.30	DISCUSS TRANSACTION WITH CLIENT (1.0); REVIEW TRANSACTIONAL MATERIALS (2.0); COORDINATE OTHER TRANSACTION MATTERS (1.3).
----------	----------	------	--

FRIZZO A	10/18/22	0.40	DISCUSS TRANSACTION WITH INTERNAL TEAM (0.4).
----------	----------	------	---

FRIZZO A	10/20/22	2.50	REVIEW TRANSACTIONAL MATERIALS (2.5).
----------	----------	------	---------------------------------------

FRIZZO A	10/21/22	0.70	PARTICIPATE IN CALL WITH CLIENT TO DISCUSS DILIGENCE (0.7).
----------	----------	------	---

FRIZZO A	10/25/22	2.50	PREPARE FOR AND DISCUSS ISSUES WITH CLIENT (2.5).
----------	----------	------	---

FRIZZO A	10/28/22	0.30	COORDINATE REVIEW OF DOCUMENTS (0.3).
----------	----------	------	---------------------------------------

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FRIZZO A	10/31/22	0.50	DISCUSS ISSUES WITH CLIENT AND OUTSIDE COUNSEL (0.5).
		13.90	
VAN KAN BM	10/17/22	0.40	REVIEW TRANSACTION BACKGROUND AND MATERIALS (0.4).
VAN KAN BM	10/25/22	1.20	PREPARE FOR CALL DISCUSSING TRADEMARK AND IP ISSUES (0.5); PARTICIPATE IN CALL RE: SAME (0.7).
VAN KAN BM	10/31/22	0.80	PREPARE FOR CALL DISCUSSING TRADEMARK ISSUES (0.4); PARTICIPATE IN CALL RE: SAME (0.4).
		2.40	
YUH C	10/16/22	2.90	DRAFT MATERIALS RE: TRANSACTION (2.9).
YUH C	10/16/22	1.50	REVIEW TRANSACTIONAL MATERIALS (1.5).
YUH C	10/17/22	0.40	REVIEW PROPOSED DEAL TIMELINE (0.4).
YUH C	10/17/22	1.50	CALL WITH CLIENT RE: LEGAL KICKOFF (1.5).
YUH C	10/18/22	0.20	PUT TOGETHER WORKING GROUP LIST (0.2).
YUH C	10/19/22	1.60	DRAFT TRANSACTIONAL MATERIALS (1.6).
YUH C	10/20/22	1.40	CONTINUE TO DRAFT TRANSACTIONAL MATERIALS (1.4).
YUH C	10/21/22	1.00	CALL WITH CLIENT AND CONSULTANT TO DISCUSS DILIGENCE REQUESTS (1.0).
YUH C	10/24/22	1.60	REVIEW AND REVISE PROCESS LETTER (1.6).
YUH C	10/25/22	2.10	CALL WITH CLIENT TO DISCUSS AGREEMENTS (1.0); REVIEW MATERIALS SHARED BY CLIENT (1.1).
YUH C	10/31/22	0.70	TELECONFERENCE WITH CLIENT TO DISCUSS TRANSACTION MATTERS (0.7).
		14.90	
Total Associate		31.20	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

MATTER TOTAL

47.40

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

Purdue Pharma L.P.
Corporate/Transactional Advice

Bill Date: 11/14/22
Bill Number: 1917957

NAME	DATE	HOURS	DESCRIPTION
CHAN AH	10/11/22	2.80	ANALYZE TRANSACTIONAL DOCUMENTS (2.8).
CHAN AH	10/12/22	0.50	REVISE ANALYSIS RE: TRANSACTIONAL ISSUE (0.5).
		3.30	
Total Associate		3.30	
MATTER TOTAL		<u>3.30</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
DOJBill Date: 11/14/22
Bill Number: 1917955

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	10/04/22	1.10	PREPARE FOR BOARD MEETING (0.3); ATTEND BOARD MEETING (0.8).
BRAGG JL	10/05/22	0.70	CONFER WITH CLIENT RE: SUBPOENA (0.4); CONFER WITH CO-COUNSEL RE: COUNSEL ISSUE (0.3).
BRAGG JL	10/06/22	1.40	CALL WITH CLIENT RE: EMPLOYEE REPRESENTATION ISSUES (0.7); CONFER WITH EMPLOYEE RE: REPRESENTATION (0.3); CONFER WITH CO-COUNSEL RE: REPRESENTATION (0.4).
BRAGG JL	10/07/22	1.20	REVIEW AND ANALYZE WHITE PAPER (0.7); CONFER WITH CO-COUNSEL RE: CLAIMS IMPLICATING DOJ MATTERS (0.5).
BRAGG JL	10/10/22	0.70	CONFER WITH EMPLOYEE COUNSEL RE: DOCUMENT ISSUES (0.7).
BRAGG JL	10/12/22	1.40	CONFER WITH CO-COUNSEL RE: WHITE PAPER (0.6); REVIEW AND ANALYZE WHITE PAPER (0.8).
BRAGG JL	10/13/22	0.90	CONFER WITH CO-COUNSEL RE: PRIVILEGE ISSUES (0.4); CONFER WITH CO-COUNSEL RE: STUDY ANALYSIS (0.5).
BRAGG JL	10/14/22	0.40	CONFER WITH CO-COUNSEL RE: DOJ MATTERS (0.4).
BRAGG JL	10/17/22	0.30	CONFER WITH CLIENT AND CO-COUNSEL RE: DOJ MATTER (0.3).
BRAGG JL	10/18/22	0.20	CONFER WITH CLIENT AND CO-COUNSEL RE: PRIVILEGE ISSUES (0.2).
BRAGG JL	10/20/22	1.00	CONFER WITH CO-COUNSEL RE: PRIVILEGE ISSUES (0.4); CONFER WITH CLIENT RE: DOJ REQUEST (0.6).
BRAGG JL	10/25/22	0.50	REVIEW AND EDIT DOJ INFORMATION IN INSURANCE SUBMISSION (0.5).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

BRAGG JL	10/26/22	0.90	CONFER WITH CLIENT RE: REPRESENTATION ISSUES (0.3); OUTREACH TO FORMER EMPLOYEES RE: REPRESENTATION ISSUES (0.6).
BRAGG JL	10/27/22	1.10	ATTEND BOARD MEETING (1.1).
BRAGG JL	10/28/22	2.00	CONFER WITH M. FLORENCE RE: DOJ PRODUCTION ISSUES (0.6); CONFER WITH CO-COUNSEL RE: SENTENCING ISSUES (0.3); REVIEW AND ANALYZE DOJ DOCUMENTS (0.5); READ SENTENCING RELATED CASE LAW (0.6).
BRAGG JL	10/31/22	0.90	REVIEW MATERIALS PERTAINING TO DOJ REQUEST (0.3); CONFER WITH CO-COUNSEL RE: DEVELOPMENT OF RESPONSE TO DOJ REQUEST (0.6).

14.70

FITZGERALD P	10/03/22	0.40	ATTENTION TO CLIENT REQUEST (0.2); UPDATE CALL WITH M. FLORENCE (0.2).
FITZGERALD P	10/04/22	0.50	ATTEND SPECIAL COMMITTEE MEETING (0.5).
FITZGERALD P	10/05/22	0.20	ATTENTION TO SUBPOENA (0.2).
FITZGERALD P	10/07/22	0.50	ATTENTION TO UPDATE (0.1); CALL WITH CLIENT, DAVIS POLK AND SKADDEN TEAMS REGARDING SENTENCING COORDINATION (0.4).
FITZGERALD P	10/10/22	1.50	ATTENTION TO SENTENCING ISSUES (0.9); REVIEW AND EDIT DRAFT RESPONSE TO DOJ REQUEST (0.6).
FITZGERALD P	10/11/22	0.10	REVIEW DRAFT MEMO TO DOJ (0.1).
FITZGERALD P	10/12/22	0.60	INTERNAL SKADDEN DISCUSSION REGARDING PRIVILEGE ISSUES (0.5); REVIEW DRAFT DOCUMENT (0.1).
FITZGERALD P	10/13/22	0.30	CALL WITH COUNSEL RE: REQUEST (0.1); UPDATE WITH M FLORENCE (0.2).
FITZGERALD P	10/15/22	0.30	WRITE SUMMARY UPDATE FOR CLIENT (0.3).
FITZGERALD P	10/16/22	0.30	WRITE SUMMARY UPDATE FOR CLIENT (0.3).
FITZGERALD P	10/18/22	0.10	ATTENTION TO PRIVILEGE QUESTION (0.1).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FITZGERALD P	10/20/22	0.60	CALL REGARDING PRIVILEGE ISSUE WITH SKADDEN TEAM (0.5); REVIEW UPDATE (0.1).
FITZGERALD P	10/24/22	0.50	REVIEW DRAFT COURT FILING REGARDING DOJ ISSUES (0.5).
FITZGERALD P	10/25/22	0.10	ATTENTION TO PRIVILEGE ISSUE (0.1).
FITZGERALD P	10/26/22	0.50	ATTENTION TO PRIVILEGE ISSUE (0.5).
FITZGERALD P	10/27/22	0.30	ATTENTION TO PRIVILEGE ISSUE (0.3).
FITZGERALD P	10/28/22	1.30	ATTENTION TO PRIVILEGE ISSUE (1.3).
		8.10	
FLORENCE MP	10/02/22	0.90	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (0.9).
FLORENCE MP	10/03/22	3.60	CONFER WITH CO-COUNSEL RE: PRIVILEGE ISSUES (1.2); FOLLOW UP RE: SAME (0.6); REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (1.2); CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.4); CONFER WITH P. FITZGERALD RE: SAME (0.2).
FLORENCE MP	10/04/22	3.00	PREPARE FOR AND ATTEND SPECIAL COMMITTEE MEETING (0.6); REVIEW AND ANALYZE MATERIALS RE: TOPICS OF DOJ INTEREST (0.4); CORRESPOND WITH CO-COUNSEL AND CONSULTANT RE: PRODUCTIONS (0.5); REVIEW AND EDIT DRAFT ANALYSIS RE: TOPIC OF DOJ INTEREST (1.5).
FLORENCE MP	10/06/22	6.20	ATTENTION TO DOJ PRODUCTION QUESTIONS (0.7); REVIEW AND REVISE ANALYSIS RE: TOPIC OF DOJ INTEREST (5.5).
FLORENCE MP	10/07/22	3.70	CONFER WITH J. BRAGG RE: DRAFT SUBMISSION (0.2); CONFER WITH W. BEJAN AND A. CHAN RE: SAME (0.4); CONFER WITH CO-COUNSEL RE: TOPICS OF DOJ INTEREST (0.6); PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: SENTENCING ISSUES (0.6); REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (1.7); CORRESPOND WITH CO-COUNSEL RE: CLIENT QUESTION (0.2).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**ATTORNEY WORK PRODUCT****PRIVILEGED AND CONFIDENTIAL**

FLORENCE MP	10/09/22	0.90	REVIEW AND EDIT DRAFT ANALYSIS RE: TOPIC OF DOJ INTEREST (0.9).
FLORENCE MP	10/10/22	1.90	CORRESPOND WITH SKADDEN TEAM RE: DRAFT ANALYSIS RE: TOPIC OF DOJ INTEREST (0.7); CORRESPOND WITH VENDOR RE: DOJ PRODUCTIONS (0.3); REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (0.9).
FLORENCE MP	10/11/22	3.80	CORRESPOND WITH PRODUCTION TEAM RE: DOJ MATTERS (0.2); REVIEW AND EDIT DRAFT ANALYSIS RE: TOPIC OF DOJ INTEREST (3.3); CONFER WITH W. BEJAN RE: SAME (0.3).
FLORENCE MP	10/12/22	4.80	CORRESPOND WITH SKADDEN TEAM RE: DRAFT ANALYSIS RE: TOPIC OF DOJ INTEREST (0.2); CONFER WITH SKADDEN TEAM RE: SAME (0.5); REVISE AND FINALIZE SAME (0.8); CONFER WITH CO-COUNSEL RE: DOJ REQUESTS (1.2); FOLLOW UP RE: SAME (0.2); REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (1.9).
FLORENCE MP	10/13/22	6.70	PREPARE FOR CALL WITH DOJ RE: REQUEST (0.2); FOLLOW UP WITH R. HOFF RE: SAME (0.7); REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (4.6); CONFER WITH SKADDEN TEAM RE: DOJ MATTER STATUS (0.3); CONFER WITH J. BRAGG AND W. BEJAN RE: TOPIC OF DOJ INTEREST (0.6).
FLORENCE MP	10/14/22	2.00	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (1.5); CONFER WITH CO-COUNSEL RE: DOJ PRODUCTION WORKSTREAMS (0.5).
FLORENCE MP	10/16/22	0.60	PARTICIPATE IN CALL WITH CO-COUNSEL RE: PRODUCTIONS (0.3); REVIEW DOCUMENTS IN CONNECTION WITH SAME (0.3).
FLORENCE MP	10/17/22	1.50	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (1.5).
FLORENCE MP	10/18/22	0.50	CONFER WITH SKADDEN TEAM RE: MATTER STATUS (0.5).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	10/19/22	1.40	CORRESPOND WITH CO-COUNSEL RE: DOJ REQUESTS (0.6); CORRESPOND WITH W. BEJAN RE: SAME (0.3); REVIEW AND ANALYZE MATERIALS RE: TOPICS OF DOJ INTEREST (0.3); REVIEW AND EDIT DRAFT PRODUCTION LETTER (0.2).
FLORENCE MP	10/20/22	2.90	CONFER WITH W. BEJAN RE: DOJ REQUEST (0.1); CORRESPOND WITH SKADDEN TEAM RE: SAME (0.4); CORRESPOND WITH VENDOR RE: UPCOMING PRODUCTIONS (0.2); CONFER WITH CO-COUNSEL RE: SAME (0.5); CONFER WITH P. FITZGERALD AND J. BRAGG RE: DOJ ISSUES (0.6); PREPARE CALL WITH CLIENT AND CO-COUNSEL RE: LITIGATION REQUESTS (0.3); PARTICIPATE IN CALL RE: SAME (0.8).
FLORENCE MP	10/21/22	0.40	CORRESPOND WITH CO-COUNSEL RE: DOJ REQUESTS (0.4).
FLORENCE MP	10/24/22	2.40	CORRESPOND WITH CO-COUNSEL AND CONSULTANT RE: UPCOMING PRODUCTIONS (1.2); CORRESPOND WITH J. BRAGG AND W. BEJAN RE: DOJ REQUESTS (1.1); REVIEW DRAFT RE: INSURANCE ADVERSARY MATTER (0.1).
FLORENCE MP	10/25/22	1.80	CORRESPOND WITH CO-COUNSEL RE: DISCOVERY REQUESTS (1.2); CORRESPOND WITH CO-COUNSEL RE: DOCUMENT REVIEW (0.3); CORRESPOND WITH CO-COUNSEL RE: PRIVILEGE LOG REVIEW (0.3).
FLORENCE MP	10/26/22	1.80	CORRESPOND WITH CO-COUNSEL RE: PREPARATION FOR BOARD MEETING (0.3); CORRESPOND WITH CO-COUNSEL RE: INSURANCE LITIGATION (0.2); CONFER WITH CO-COUNSEL RE: DOCUMENTS OF DOJ INTEREST (0.3); REVIEW AND ANALYZE SAME (1.0).
FLORENCE MP	10/27/22	1.50	CORRESPOND WITH CO-COUNSEL AND CONSULTANT RE: DOCUMENT REVIEW AND PRODUCTIONS (0.5); CORRESPOND WITH W. BEJAN RE: TOPIC OF DOJ INTEREST (0.2); ATTEND BOARD MEETING (0.8).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	10/28/22	3.60	CONFER WITH CO-COUNSEL RE: DOJ REQUESTS (0.3); CONFER WITH J. BRAGG RE: SAME (0.1); CONFER WITH DOJ RE: SAME (0.2); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: PRESS INQUIRY (1.0); CORRESPOND WITH SKADDEN TEAM RE: DOJ STATUS (0.3); REVIEW AND EDIT DRAFT TRANSMITTAL LETTER (0.6); DRAFT AND TRANSMIT EMAIL RE: DOJ PRODUCTIONS (0.8); CORRESPOND WITH CO-COUNSEL RE: SAME (0.3).
-------------	----------	------	--

FLORENCE MP	10/31/22	1.30	CORRESPOND WITH CO-COUNSEL AND VENDOR RE: DOJ PRODUCTIONS (0.5); CONFER WITH CO-COUNSEL RE: SAME (0.3); CALL WITH J. BRAGG AND W. BEJAN RE: TOPIC OF DOJ INTEREST (0.5).
-------------	----------	------	--

57.20

RIDGWAY W	10/12/22	0.50	CONFER INTERNALLY RE: DOJ STRATEGY (0.5).
-----------	----------	------	---

RIDGWAY W	10/14/22	0.60	CONFER INTERNALLY RE: DOJ ISSUES (0.6).
-----------	----------	------	---

RIDGWAY W	10/17/22	0.40	REVIEW PRIVILEGE ISSUE (0.4).
-----------	----------	------	-------------------------------

RIDGWAY W	10/20/22	0.90	CONFER WITH Y. PATEL RE: RESEARCH AND STRATEGY (0.5); REVIEW MATERIALS RE: PRIVILEGE ISSUES (0.4).
-----------	----------	------	--

RIDGWAY W	10/26/22	0.90	ANALYZE RESEARCH RE: PRIVILEGE ISSUES (0.6); CONFER WITH P. FITZGERALD RE: STRATEGY (0.3).
-----------	----------	------	--

RIDGWAY W	10/27/22	0.40	FOLLOW UP RE: PRIVILEGE ANALYSIS (0.4).
-----------	----------	------	---

RIDGWAY W	10/28/22	0.70	ANALYZE MATERIALS RE: DOJ ISSUES (0.4); CONFER WITH Y. PATEL RE: SENTENCING ISSUES (0.3).
-----------	----------	------	---

RIDGWAY W	10/31/22	1.00	CONFER WITH Y. PATEL RE: RESEARCH (0.4); REVIEW RESEARCH ON SENTENCING (0.6).
-----------	----------	------	---

5.40

Total Partner		85.40	
----------------------	--	--------------	--

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**ATTORNEY WORK PRODUCT****PRIVILEGED AND CONFIDENTIAL**

BEJAN WA	10/03/22	0.20	CALL WITH SKADDEN TEAM RE: TOPICS OF DOJ INTEREST (0.2).
BEJAN WA	10/03/22	0.40	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (0.4).
BEJAN WA	10/06/22	0.50	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (0.5).
BEJAN WA	10/07/22	1.70	CALL WITH SKADDEN TEAM RE: TOPICS OF DOJ INTEREST (1.7).
BEJAN WA	10/07/22	2.70	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (2.7).
BEJAN WA	10/08/22	2.30	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (2.3).
BEJAN WA	10/10/22	0.70	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (0.7).
BEJAN WA	10/11/22	1.90	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (1.9).
BEJAN WA	10/13/22	0.60	CALL WITH SKADDEN TEAM RE: TOPICS OF DOJ INTEREST (0.6).
BEJAN WA	10/20/22	3.60	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (3.6).
BEJAN WA	10/21/22	1.40	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (1.4).
BEJAN WA	10/24/22	0.40	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (0.4).
BEJAN WA	10/25/22	2.20	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (2.2).
BEJAN WA	10/26/22	3.70	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (3.7).
BEJAN WA	10/27/22	3.30	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (3.3).
BEJAN WA	10/28/22	0.30	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (0.3).
BEJAN WA	10/30/22	0.60	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (0.6).
BEJAN WA	10/31/22	0.50	CALL WITH SKADDEN TEAM RE: TOPICS OF DOJ INTEREST (0.5).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

BEJAN WA	10/31/22	1.70	REVIEW AND ANALYZE DOCUMENTS RE: TOPICS OF DOJ INTEREST (1.7).
28.70			
CHAN AH	10/03/22	0.20	CONFER ON PRIVILEGE LOG RE: DOJ TOPICS OF INTEREST (0.2).
CHAN AH	10/03/22	2.20	DRAFT PRIVILEGE LOG RE: DOJ TOPICS OF INTEREST (2.2).
CHAN AH	10/03/22	1.30	REVISE WHITE PAPER RE: DOJ TOPICS OF INTEREST (1.3).
CHAN AH	10/04/22	0.10	CONFER ON NEXT STEPS RE: DOJ TOPICS OF INTEREST (0.1).
CHAN AH	10/05/22	0.90	REVISE DOCUMENTS RE: DOJ TOPICS OF INTEREST (0.9).
CHAN AH	10/06/22	1.20	REVISE SUBMISSION RE: DOJ TOPICS OF INTEREST (1.2).
CHAN AH	10/07/22	4.20	REVISE SUBMISSION RE: DOJ TOPICS OF INTEREST (4.2).
CHAN AH	10/07/22	0.50	CONFER ON SUBMISSION RE: DOJ TOPICS OF INTEREST (0.5).
CHAN AH	10/09/22	1.80	REVISE SUBMISSION RE: DOJ TOPICS OF INTEREST (1.8).
CHAN AH	10/10/22	1.40	REVISE SUBMISSION RE: DOJ TOPICS OF INTEREST (1.4).
CHAN AH	10/11/22	0.50	CONDUCT FOLLOW UP ON SUBMISSION RE: DOJ TOPICS OF INTEREST (0.5).
CHAN AH	10/12/22	0.30	REVIEW SUBMISSION RE: DOJ TOPIC OF INTEREST (0.3).
14.60			
HELLMAN E	10/05/22	5.40	REVISE MATERIALS RE: DOJ TOPICS OF INTEREST (5.4).
HELLMAN E	10/06/22	2.50	REVISE MATERIALS RE: DOJ TOPICS OF INTEREST (2.5).
HELLMAN E	10/07/22	1.00	CONFER IN FIRM RE: TOPICS OF DOJ INTEREST (1.0).
8.90			

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

PATEL YP	10/20/22	0.20	CALL WITH W. RIDGEWAY REGARDING RESEARCH ON PRIVILEGE (0.2).
PATEL YP	10/22/22	3.00	RESEARCH PRIVILEGE ISSUES (3.0).
PATEL YP	10/24/22	0.20	CONFER WITH P. FITZGERALD REGARDING PRIVILEGE RESEARCH (0.2).
PATEL YP	10/25/22	5.60	RESEARCH PRIVILEGE ISSUES (5.6).
PATEL YP	10/31/22	0.10	CALL WITH W. RIDGEWAY REGARDING RESEARCH AND ANALYSIS (0.1).

9.10**Total Associate 61.30**

FIEBERG WR	10/05/22	2.20	RETRIEVE ADDITIONAL WHITE PAPER DOCUMENTS FROM RELATIVITY (2.2).
FIEBERG WR	10/10/22	0.50	PERFORM DATABASE SEARCH TO (0.5).

2.70

HOHMANN MJ	10/06/22	2.80	COMMUNICATE WITH ATTORNEY RE: SUPPLEMENTAL RESPONSES (0.3); CONFER WITH TEAM RE: DATABASE ACCESS (0.1); CREATE DATABASE LOGIN (0.1); REVIEW REQUESTS (2.0); DRAFT EMAIL TO ATTORNEY (0.3).
------------	----------	------	--

2.80**Total Legal Assistant 5.50****MATTER TOTAL 152.20**

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates
ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

Purdue Pharma L.P.
General Advice

Bill Date: 11/14/22
Bill Number: 1917951

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	10/01/22	2.90	DEVELOP MATERIALS FOR MONITOR BRIEFING (2.1); CONFER WITH CLIENT RE: REGULATORY EXPERT ASSISTANCE (0.3); DRAFT FDA LETTER (0.5).
BRAGG JL	10/03/22	2.10	PREPARE FOR CALL WITH MONITOR (0.7); CALL WITH MONITOR (0.4); CONFER WITH CLIENT RE: REGULATORY MATTERS (0.3); CALL WITH CLIENT TO PREPARE FOR MONITOR CALL (0.4); REVIEW REGULATORY MATERIALS (0.3).
BRAGG JL	10/04/22	2.20	REVIEW REGULATORY MATERIALS (0.6); CALL WITH CO-COUNSEL RE: REGULATORY MATERIALS (0.5); CALL WITH CLIENT RE: REGULATORY MATERIALS (0.5); CONFER WITH CLIENT RE: REGULATORY CONSULTANTS (0.3); CALL WITH CLIENT RE: RETAIL CHANNEL ISSUES (0.3).
BRAGG JL	10/05/22	3.00	CONFER WITH CLIENT RE: REGULATORY ISSUES (1.0); REVIEW AND EDIT CORRESPONDENCE (0.6); CONFER WITH CLIENT RE: REGULATORY MATTERS (0.6); WORKING MEETING WITH CLIENT RE: CONSULTANT MATTERS (0.5); CONFER WITH CONSULTANT RE: REVIEW (0.3).
BRAGG JL	10/06/22	4.10	CALL WITH EXPERT RE: REGULATORY MATTERS (0.6); DRAFT CORRESPONDENCE TO EXPERT (0.9); CONFER WITH CLIENT (0.6); CONFER WITH CLIENT RE: 867 DATA ISSUE (0.6); CONFER WITH CLIENT RE: REGULATORY ISSUES (0.4); CONFER WITH CLIENT RE: MATTERS (0.4); CONFER WITH CLIENT RE: REGULATORY EXPERT (0.3); REVIEW AND EDIT LETTER (0.3).
BRAGG JL	10/07/22	2.10	CONFER WITH CO-COUNSEL RE: REGULATORY SUBMISSION MATTERS (0.6); REVIEW MATERIALS (0.8); CONFER WITH CO-COUNSEL RE: DONATION ISSUES (0.7).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates
ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

BRAGG JL	10/10/22	2.20	REVIEW AND ANALYZE DONATION MATERIALS (0.8); CONFER WITH CO-COUNSEL RE: DONATION ISSUES (0.8); CONFER WITH CLIENT RE: PHARMACY AGREEMENT (0.6).
BRAGG JL	10/11/22	4.10	STRATEGY DISCUSSION WITH CLIENT RE: REGULATORY ISSUES (0.9); CONFER WITH CO-COUNSEL RE: REGULATORY ISSUES (0.4); REVIEW AND EDIT FDA LETTER (0.7); REVIEW ANALYSIS MATERIALS (0.6); CONFER WITH CLIENT RE: RECALL ISSUES (0.4); ATTENTION TO VA TALKING POINTS (0.2); CONFER WITH CLIENT RE: FDA ISSUES (0.3); CONFER WITH CLIENT RE: MONITOR REQUEST REGARDING REGULATORY MATTERS (0.6).
BRAGG JL	10/12/22	3.50	STRATEGY DISCUSSION WITH CLIENT RE: REGULATORY MATTERS (1.0); REVIEW AND EDIT FDA LETTER (0.6); CONFER WITH CLIENT RE: FDA OUTREACH (0.5); CONFER WITH CLIENT RE: REGULATORY ISSUE (0.4); FINALIZE AGREEMENT (0.6); REVIEW AND ANALYZE LEGACY CONTRACT ISSUES (0.4).
BRAGG JL	10/13/22	1.50	CONFER WITH CO-COUNSEL RE: REGULATORY ISSUES (0.4); DRAFT FDA CORRESPONDENCE REGARDING CUSTOMER INQUIRY (0.6); CONFER WITH CO-COUNSEL RE: DONATIONS PROGRAM (0.5).
BRAGG JL	10/14/22	0.40	CONFER WITH CLIENT RE: REGULATORY MATTERS (0.4).
BRAGG JL	10/17/22	0.60	CONFER WITH CLIENT RE: FDA INQUIRY (0.3); CONFER WITH CLIENT RE: REGULATORY MATTER (0.3).
BRAGG JL	10/18/22	2.40	CALL RE: BACKGROUND (1.0); CONFER WITH CLIENT RE: REGULATORY MATTERS (0.6); CALL WITH CLIENT RE: REGULATORY UPDATE (0.5); REVIEW UPDATE OF REGULATORY ISSUES (0.3).
BRAGG JL	10/20/22	0.50	CONFER WITH CO COUNSEL REGARDING REGULATORY ISSUES (0.5).
BRAGG JL	10/21/22	0.90	REVIEW REGULATORY RELATED BOARD MATERIALS (0.5); CONFER WITH CLIENT RE: DATA USE AGREEMENT (0.4).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

BRAGG JL	10/25/22	2.20	CONFER WITH CLIENT RE: REGULATORY MATTERS (0.3); REVIEW AND EDIT COMPLIANCE MATERIALS (1.9).
BRAGG JL	10/26/22	0.30	REVISE AND EDIT DRAFT LANGUAGE RE: REGULATORY ISSUES (0.3).
BRAGG JL	10/27/22	1.20	CONFER WITH CLIENT RE: COMPLIANCE MATERIALS (0.6); CONFER WITH CLIENT RE: INFORMATION SHARING WITH VENDOR (0.6).
BRAGG JL	10/28/22	1.20	REVIEW AND ANALYZE REGULATORY MATERIALS (0.7); CALL WITH CLIENT RE: REGULATORY MATTERS (0.5).
BRAGG JL	10/31/22	1.80	CONFER WITH CLIENT RE: REGULATORY MATTERS (0.3); STRATEGY DISCUSSION WITH CLIENT AND CO-COUNSEL RE: REGULATORY MATTERS (1.5).

39.20

DUNN AM	10/04/22	0.80	REVIEW BACKGROUND MATERIALS (0.4); PARTICIPATE ON CALL WITH CLIENT AND J. BRAGG (0.8).
DUNN AM	10/06/22	0.50	PARTICIPATE ON CALL WITH CLIENT AND CO-COUNSEL WITH RE: PRODUCT (0.5).
DUNN AM	10/07/22	0.40	PARTICIPATE ON CALL WITH CLIENT RE: REGULATORY ISSUES (0.4).
DUNN AM	10/07/22	0.30	PARTICIPATE ON CALL WITH P. AMAECHI RE: REGULATORY MATTERS (0.3).
DUNN AM	10/10/22	1.20	DRAFT TALKING POINTS RE: DONATION PROGRAM (1.2).
DUNN AM	10/10/22	0.80	PARTICIPATE ON CALL WITH J. BRAGG, M. FLORENCE AND P. AMAECHI RE: DONATION PROGRAM (0.8).
DUNN AM	10/11/22	4.40	REVIEW BACKGROUND MATERIALS RE: PROGRAMS (3.0); PARTICIPATE ON CALL WITH CO-COUNSEL RE: SAME (1.4).
DUNN AM	10/12/22	0.50	PARTICIPATE ON CALL WITH A. CHAN AND T. DAVIS RE: CEASE-AND-DESIST LETTER (0.5).
DUNN AM	10/13/22	0.50	PARTICIPATE ON CALL WITH M. FLORENCE AND J. BRAGG RE: DONATION PROGRAMS (0.5).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

DUNN AM	10/26/22	2.10	REVIEW RESEARCH RE: REGULATORY MATTERS (2.1).
DUNN AM	10/28/22	0.70	REVIEW DRAFT REGULATORY MATERIALS (0.7).
DUNN AM	10/31/22	4.70	REVIEW RESEARCH FINDINGS RE: CEASE AND DESIST LETTER (4.7).

16.90

FITZGERALD P	10/03/22	0.50	UPDATE CALL WITH CO-COUNSEL, J. BRAGG, AND M. FLORENCE (0.5).
--------------	----------	------	---

0.50

FLORENCE MP	10/02/22	0.10	CORRESPOND WITH CLIENT RE: REGULATORY MATTER (0.1).
FLORENCE MP	10/03/22	3.20	PARTICIPATE IN CALL WITH CO-COUNSEL RE: REGULATORY MATTERS (0.5); CONDUCT INTERVIEWS RE: REGULATORY MATTER (2.5); CORRESPOND WITH CLIENT RE: STATUS OF REGULATORY SUBMISSION (0.2).
FLORENCE MP	10/04/22	1.10	CONFER WITH SKADDEN TEAM RE: REGULATORY MATTER STATUS (0.4); PARTICIPATE IN STATUS CALL WITH CLIENT RE: REGULATORY MATTER (0.7).
FLORENCE MP	10/06/22	0.40	CORRESPOND WITH CLIENT RE: REGULATORY MATTER (0.2); CONFER WITH DOJ RE: SAME (0.2).
FLORENCE MP	10/07/22	2.40	REVIEW AND EDIT STATUS UPDATE RE: REGULATORY MATTER (0.9); CORRESPOND WITH L. DICKS-MIREAUX RE: SAME (0.2); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: SAME (0.5); CONFER WITH CO-COUNSEL RE: REGULATORY MATTER (0.5); CONFER WITH A. DUNN RE: REGULATORY QUESTION (0.1); CORRESPOND WITH CLIENT RE: REGULATORY SUBMISSION (0.2).
FLORENCE MP	10/10/22	1.30	CORRESPOND WITH CLIENT RE: REGULATORY MATTER STATUS (0.3); CONFER WITH A. DUNN AND J. BRAGG RE: PRODUCT DONATION PROGRAM (1.0).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**ATTORNEY WORK PRODUCT****PRIVILEGED AND CONFIDENTIAL**

FLORENCE MP	10/11/22	1.50	CORRESPOND WITH CLIENT RE: NEXT STEPS ON REGULATORY MATTER (0.8); REVIEW DRAFT DOCUMENTS RE: SAME (0.3); CORRESPOND WITH CLIENT RE: REGULATORY SUBMISSION (0.1); CORRESPOND WITH SKADDEN TEAM RE: PROPOSED PROGRAM (0.3).
FLORENCE MP	10/12/22	1.70	PARTICIPATE IN CALLS WITH CLIENT RE: REGULATORY MATTER (0.9); CONFERENCE CALL WITH CLIENT AND J. BRAGG RE: STATUS OF REGULATORY MATTERS (0.8).
FLORENCE MP	10/13/22	2.30	CONFER WITH CLIENT PERSONNEL AND L. DICKS-MIREAUX RE: REGULATORY MATTER (1.0); CONFER WITH CLIENT AND CO-COUNSEL RE: SAME (0.4); REVIEW DRAFT EMAIL REVIEW PARAMETERS FOR SAME (0.4); CONFER WITH J. BRAGG AND A. DUNN RE: CLIENT REGULATORY QUESTIONS (0.5).
FLORENCE MP	10/14/22	0.40	CORRESPOND WITH CLIENT AND CO-COUNSEL RE: PROPOSED EMAIL REVIEW (0.4).
FLORENCE MP	10/17/22	1.60	CORRESPOND WITH L. DICKS-MIREAUX AND CLIENT RE: PROPOSED EMAIL REVIEW (0.1); DRAFT AND REVISE STATUS UPDATE RE: REGULATORY MATTER (1.5).
FLORENCE MP	10/18/22	2.70	REVIEW ANALYSIS RE: REGULATORY MATTER (1.1); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: EMAIL REVIEW FOR SAME (0.4); CORRESPOND WITH CLIENT RE: STATUS UPDATE (0.2); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: SUBMISSION (0.5); PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: SAME (0.5).
FLORENCE MP	10/19/22	0.60	REVIEW AND EDIT ANALYSIS RE: REGULATORY MATTER (0.4); CORRESPOND WITH L. DICKS-MIREAUX AND CLIENT RE: EMAIL REVIEW (0.2).
FLORENCE MP	10/20/22	0.90	CORRESPOND WITH CO-COUNSEL AND L. DICKS-MIREAUX RE: EMAIL REVIEW (0.3); CORRESPOND WITH CLIENT AND J. BRAGG RE: SAME (0.2); PREPARE FOR CALL WITH CLIENT AND CO-COUNSEL RE: REGULATORY MATTER (0.2); PARTICIPATE IN CALL RE: SAME (0.2).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**ATTORNEY WORK PRODUCT****PRIVILEGED AND CONFIDENTIAL**

FLORENCE MP	10/24/22	0.80	CORRESPOND WITH CLIENT RE: MATTER STATUS (0.4); CONFER WITH L. DICKS-MIREAUX RE: EMAIL REVIEW (0.4).
FLORENCE MP	10/25/22	0.60	CORRESPOND WITH L. DICKS-MIREAUX RE: EMAIL REVIEW (0.3); CONFER WITH CO-COUNSEL RE: REGULATORY MATTER (0.3).
FLORENCE MP	10/27/22	0.20	CORRESPOND WITH L. DICKS-MIREAUX RE: EMAIL REVIEW (0.2).
FLORENCE MP	10/28/22	0.90	PREP CALL WITH CLIENT RE: REGULATORY MATTER (0.2); CONFER WITH L. DICKS-MIREAUX RE: SAME (0.2); REVIEW SUMMARY RE: EMAIL REVIEW (0.3); CONFER WITH A. DUNN RE: DRAFT AGREEMENT (0.2).
FLORENCE MP	10/31/22	0.80	CONFER WITH CLIENT RE: REGULATORY MATTER STATUS (0.8).

23.50

MCCONAGHA W	10/02/22	1.40	REVIEW AND REVISE TALKING POINTS (1.0); REVIEW AND REVISE UPDATES TO DRAFT LETTER TO FDA (0.4).
MCCONAGHA W	10/03/22	0.40	REVIEW AND REVISE UPDATED LETTER TO FDA (0.4).
MCCONAGHA W	10/03/22	0.40	DISCUSSION WITH CO-COUNSEL ON FDA ENGAGEMENT STRATEGY (0.4).
MCCONAGHA W	10/05/22	0.60	CALL ON REGULATORY MATTERS (0.6).
MCCONAGHA W	10/06/22	0.40	DISCUSSION OF STRATEGY AND RELATED ISSUES WITH CO-COUNSEL (0.4).
MCCONAGHA W	10/06/22	0.60	CALL REGARDING SUPPORT RE: REGULATORY ISSUES (0.6).
MCCONAGHA W	10/10/22	0.40	REVIEW UPDATES RELATED TO FDA MEETING REQUEST (0.4).
MCCONAGHA W	10/11/22	0.60	CALL WITH CONSULTANT RE: REGULATORY MATTERS (0.6).
MCCONAGHA W	10/11/22	1.00	REVIEW AND REVISE MEETING REQUEST TO FDA (1.0).
MCCONAGHA W	10/14/22	0.60	REVIEW FINAL DRAFTS OF ENGAGEMENT LETTER (0.6).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

MCCONAGHA W	10/18/22	1.20	PREPARE FOR MEETING WITH CONSULTANT RE: REGULATORY RESPONSE (0.7); PARTICIPATE IN MEETING RE: SAME (1.2).
MCCONAGHA W	10/27/22	1.20	REVIEW MATERIALS RELATED TO LEGACY (1.2).
MCCONAGHA W	10/28/22	1.80	RESEARCH REPORTING STANDARDS (1.8).
MCCONAGHA W	10/28/22	0.60	REVIEW UPDATES TO COMPLIANCE MATERIALS (0.6).
MCCONAGHA W	10/28/22	1.40	DRAFT LEGAL ANALYSIS AND SUBMIT TO OUTSIDE COUNSEL (1.4).
MCCONAGHA W	10/31/22	0.50	CALL WITH A. DUNN ON CEASE AND DESIST LETTER; RESEARCH ON FDA T PRODUCTS (0.5).
MCCONAGHA W	10/31/22	1.20	PREPARE FOR CALL WITH REGULATORY (0.7); PARTICIPATE IN CALL RE: SAME (0.5).

14.30**Total Partner****94.40**

AMAECHI PI	10/07/22	0.20	CALL WITH A. DUNN RE: PROPOSED DONATION PROGRAM (0.2).
AMAECHI PI	10/08/22	2.70	RESEARCH ADVISORY OPINIONS RE: DONATION PROGRAM (2.7).
AMAECHI PI	10/09/22	4.20	RESEARCH AND DRAFT SUMMARY OF ADVISORY OPINIONS CONCERNING DONATION PROGRAM (4.2).
AMAECHI PI	10/10/22	5.60	RESEARCH AND DRAFT SUMMARY OF ADVISORY OPINIONS CONCERNING DONATION PROGRAM (4.9); CALL WITH J. BRAGG, A. DUNN, AND M. FLORENCE RE: SAME (0.7).
AMAECHI PI	10/11/22	1.80	RESEARCH AND DRAFT SUMMARY RE: DONATION PROGRAM (1.8).

14.50

CHAN AH	10/07/22	0.90	CONFER ON SCOPE OF RESEARCH (0.9).
CHAN AH	10/07/22	0.50	REVIEW BACKGROUND MATERIALS (0.5).
CHAN AH	10/11/22	0.80	RESEARCH ISSUE OF INTEREST; CONFER ON OUTLINE (0.8).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**ATTORNEY WORK PRODUCT****PRIVILEGED AND CONFIDENTIAL**

CHAN AH	10/12/22	0.20	DRAFT MEETING SUMMARY (0.2).
CHAN AH	10/12/22	1.00	CONFER ON LETTER RE: ISSUE OF INTEREST (1.0).
CHAN AH	10/12/22	0.60	REVIEW OUTLINE RE: ISSUE OF INTEREST (0.6).
CHAN AH	10/13/22	0.20	CONFER ON LETTER RE: ISSUE OF INTEREST (0.2).
CHAN AH	10/14/22	2.40	REVISE LETTER RE: ISSUE OF INTEREST (2.4).
CHAN AH	10/27/22	1.60	RESEARCH REGULATORY REQUIREMENTS (1.6).
CHAN AH	10/28/22	2.00	RESEARCH REGULATORY REQUIREMENTS (2.0).
CHAN AH	10/31/22	0.20	REVIEW LETTER REVISIONS (0.2).
		10.40	
DAVIS TL	10/07/22	1.80	REVIEW ONBOARDING DOCUMENTS (0.8); DISCUSS SCOPE OF RESEARCH WITH SKADDEN TEAM (1.0).
DAVIS TL	10/07/22	0.90	RESEARCH FDA REGULATORY ISSUES (0.9).
DAVIS TL	10/10/22	6.20	RESEARCH RE: CEASE-AND-DESIST LETTERS (6.2).
DAVIS TL	10/11/22	4.40	DRAFT WORK PRODUCT BASED ON RESEARCH (4.4).
DAVIS TL	10/11/22	1.40	REVIEW RESEARCH MATERIALS (1.4).
DAVIS TL	10/12/22	4.20	REVISE WORK PRODUCT (2.0); RESEARCH FEDERAL AGENCY PRECEDENT RELATED TO SUBJECT-MATTER (2.2).
DAVIS TL	10/12/22	0.60	REVIEW DRAFT WORK PRODUCT (0.6).
DAVIS TL	10/13/22	11.20	DISCUSS RESEARCH WITH SKADDEN TEAM (1.0); RESEARCH ADVISORY OPINIONS (5.0); REVISE DRAFT LETTER (5.2).
DAVIS TL	10/14/22	2.00	IMPLEMENT FINAL REVISIONS TO DRAFT LETTER (2.0).
DAVIS TL	10/17/22	2.30	RESEARCH REGARDING ENFORCEMENT PRACTICES (2.3).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**ATTORNEY WORK PRODUCT****PRIVILEGED AND CONFIDENTIAL**

DAVIS TL	10/17/22	0.20	DISCUSS RESEARCH STRATEGY WITH SKADDEN TEAM (0.2).
DAVIS TL	10/25/22	1.40	RESEARCH REGULATORY PRECEDENT (1.4).
DAVIS TL	10/28/22	3.20	RESEARCH REGULATORY PRECEDENT (1.2) AND REVISED WORK PRODUCT (2.0).

39.80

DEAN B	10/04/22	1.30	PARTICIPATE ON CALL WITH SKADDEN TEAM RE: REGULATORY MATTERS (0.8); FOLLOW UP CALL WITH D. OBANOR RE: SAME (0.1) REVIEW MATERIALS RE: REGULATORY MATTERS (0.4).
DEAN B	10/05/22	2.30	ANALYZE DOCUMENTS RE: REGULATORY ISSUES (2.3).

3.60

DICKS-MIREAUX L	10/03/22	1.40	PARTICIPATE IN WITNESS INTERVIEW WITH M. FLORENCE FOR REGULATORY MATTER (0.8); FINALIZE NOTES FROM SAME INTERVIEW (0.6).
DICKS-MIREAUX L	10/03/22	1.00	PREPARE FOR WITNESS INTERVIEW FOR REGULATORY MATTER (0.1); PARTICIPATE IN SAME INTERVIEW WITH M. FLORENCE (0.6); FINALIZE NOTES FROM SAME INTERVIEW (0.3).
DICKS-MIREAUX L	10/03/22	1.20	PREPARE FOR WITNESS INTERVIEW FOR REGULATORY MATTER (0.1); PARTICIPATE IN SAME INTERVIEW WITH M. FLORENCE (0.7); DEBRIEF WITH M. FLORENCE FROM SAME INTERVIEW (0.2); FINALIZE NOTES FROM SAME INTERVIEW (0.2).
DICKS-MIREAUX L	10/04/22	2.20	DRAFT SUMMARY OF REGULATORY MATTER FINDINGS FROM WITNESS INTERVIEWS (2.2).
DICKS-MIREAUX L	10/06/22	0.10	EMAIL M. FLORENCE TO DISCUSS NEXT STEPS IN REGULATORY MATTER (0.1).
DICKS-MIREAUX L	10/07/22	1.00	REVISE SUMMARY OF REGULATORY MATTER FINDINGS FROM WITNESS INTERVIEWS (1.0).
DICKS-MIREAUX L	10/07/22	0.10	DISCUSS VIA EMAIL WITH M. FLORENCE NEXT STEPS IN REGULATORY MATTER (0.1).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**ATTORNEY WORK PRODUCT****PRIVILEGED AND CONFIDENTIAL**

DICKS-MIREAUX L	10/11/22	2.30	DRAFT WITNESS INTERVIEW OUTLINES FOR REGULATORY MATTER (1.0); DRAFT DOCUMENT REVIEW PARAMETERS FOR SAME INVESTIGATION (1.3).
DICKS-MIREAUX L	10/12/22	0.70	PARTICIPATE IN WITNESS INTERVIEW WITH M. FLORENCE FOR REGULATORY MATTER (0.4); FINALIZE NOTES FROM SAME INTERVIEW (0.3).
DICKS-MIREAUX L	10/12/22	0.50	PARTICIPATE IN WITNESS INTERVIEW WITH M. FLORENCE FOR REGULATORY MATTER (0.3); FINALIZE NOTES FROM SAME INTERVIEW (0.2).
DICKS-MIREAUX L	10/12/22	1.10	REVISE DOCUMENT REVIEW PARAMETERS FOR REGULATORY MATTER (1.1).
DICKS-MIREAUX L	10/12/22	0.10	DISCUSS WITH M. FLORENCE NEXT STEPS IN REGULATORY MATTER (0.1).
DICKS-MIREAUX L	10/13/22	0.30	DISCUSS WITH M. FLORENCE REGULATORY MATTER (0.3).
DICKS-MIREAUX L	10/13/22	0.10	REVISE DOCUMENT REVIEW PARAMETERS FOR REGULATORY MATTER (0.1).
DICKS-MIREAUX L	10/13/22	0.10	DISCUSS WITH M. FLORENCE NEXT STEPS IN REGULATORY MATTER (0.1).
DICKS-MIREAUX L	10/13/22	0.70	PARTICIPATE IN WITNESS INTERVIEW WITH M. FLORENCE FOR REGULATORY MATTER (0.5); FINALIZE NOTES FROM SAME INTERVIEW (0.2).
DICKS-MIREAUX L	10/13/22	0.60	PARTICIPATE IN WITNESS INTERVIEW WITH M. FLORENCE FOR REGULATORY MATTER (0.4); FINALIZE NOTES FROM SAME INTERVIEW (0.2).
DICKS-MIREAUX L	10/14/22	1.40	REVISE DOCUMENT REVIEW PARAMETERS FOR REGULATORY MATTER (1.4).
DICKS-MIREAUX L	10/17/22	1.30	REVISE CLIENT SEARCH TERMS FOR REGULATORY MATTER (1.3).
DICKS-MIREAUX L	10/17/22	2.30	REVISE SUMMARY OF STATUS UPDATE FOR REGULATORY MATTER (2.3).
DICKS-MIREAUX L	10/18/22	1.40	COMMUNICATE WITH CLIENT REGARDING DOCUMENT REVIEW IN REGULATORY MATTER (1.4).
DICKS-MIREAUX L	10/18/22	0.40	FINALIZE SUMMARY RE: STATUS UPDATE FOR REGULATORY MATTER (0.4).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

DICKS-MIREAUX L	10/18/22	0.30	UPDATE J. BRAGG AND P. FITZGERALD ON STATUS OF REGULATORY MATTER (0.3).
DICKS-MIREAUX L	10/18/22	0.40	DISCUSS WITH M. FLORENCE REVISIONS TO CLIENT SEARCH TERMS FOR REGULATORY MATTER (0.4).
DICKS-MIREAUX L	10/18/22	0.80	REVIEW AND ANALYZE DATA COLLECTED IN REGULATORY MATTER (0.8).
DICKS-MIREAUX L	10/18/22	0.30	PARTICIPATE IN CALL WITH M. FLORENCE TO DISCUSS DATA AND NEXT STEPS IN REGULATORY MATTER (0.3).
DICKS-MIREAUX L	10/19/22	0.50	UPDATE SUMMARY DOCUMENT ON REGULATORY MATTER (0.5).
DICKS-MIREAUX L	10/19/22	0.20	VERIFY WITH CLIENT FINAL SEARCHES FOR DOCUMENT REVIEW IN REGULATORY MATTER (0.2).
DICKS-MIREAUX L	10/20/22	0.10	COMMUNICATE WITH M. FLORENCE RE: REGULATORY MATTER (0.1).
DICKS-MIREAUX L	10/24/22	0.40	BEGIN DOCUMENT REVIEW FOR REGULATORY MATTER (0.4).
DICKS-MIREAUX L	10/24/22	0.40	DISCUSS WITH M. FLORENCE DOCUMENT REVIEW FOR REGULATORY MATTER (0.4).
DICKS-MIREAUX L	10/25/22	3.60	CONTINUE DOCUMENT REVIEW FOR REGULATORY MATTER (3.6).
DICKS-MIREAUX L	10/25/22	0.60	CONFER WITH M. FLORENCE RE: REGULATORY MATTER (0.6).
DICKS-MIREAUX L	10/26/22	5.30	CONTINUE DOCUMENT REVIEW FOR REGULATORY MATTER (5.3).
DICKS-MIREAUX L	10/27/22	2.00	DRAFT SUMMARY OF DOCUMENT REVIEW FINDINGS IN REGULATORY MATTER (2.0).
DICKS-MIREAUX L	10/28/22	0.30	CALL WITH M. FLORENCE RE: REGULATORY MATTER (0.3).

35.50

OBANOR D	10/03/22	0.60	CALL WITH B. DEAN TO DISCUSS REGULATORY MATTER (0.1); DRAFT INTERNAL EMAIL RE: REGULATORY MATTER (0.3); REVIEW INTERNAL EMAIL RE: REGULATORY MATTER (0.2).
----------	----------	------	--

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

OBANOR D	10/04/22	3.00	INTERNAL CALL TO DISCUSS REGULATORY MATTER (0.5); REVIEW DOCUMENTS IN CONNECTION WITH REGULATORY MATTER (2.5).
OBANOR D	10/05/22	1.00	REVIEW EMAIL RE: REGULATORY MATTER (0.2); REVIEW DOCUMENTS IN CONNECTION WITH REGULATORY MATTER (0.8).
OBANOR D	10/06/22	1.50	REVIEW OF DOCUMENTS IN CONNECTION WITH REGULATORY MATTER (1.5).
		6.10	
Total Associate		109.90	
RAUCCI AM	10/17/22	4.30	CONDUCT RESEARCH REGARDING REGULATORY MATTERS (4.3).
		4.30	
Total Legal Assistant Specialist		4.30	
MATTER TOTAL		<u>208.60</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Project CatalystBill Date: 11/14/22
Bill Number: 1917958

NAME	DATE	HOURS	DESCRIPTION
GIBSON ML	10/03/22	0.80	REVIEW ADDITIONAL MATERIALS (0.4) AND CALL WITH CO-COUNSEL (0.4).
GIBSON ML	10/06/22	0.90	PREP FOR AND CALL WITH CLIENT (0.2); REVIEW UPDATED CHANGES TO CHART (0.2); REVIEW CLIENT COMMENTS ON DECK (0.2); FOLLOW UP ON SAME (0.3).
GIBSON ML	10/07/22	0.50	CONFER WITH WORKING GROUP ON RESPONSE TO TRANSACTION (0.5).
		2.20	
SCHLOSSBERG RK	10/06/22	0.60	CONFER RE: TRANSACTION RELATED MATTERS (0.6).
SCHLOSSBERG RK	10/06/22	0.30	REVIEW TRANSACTION RELATED MATTERS (0.3).
SCHLOSSBERG RK	10/07/22	1.50	REVIEW TRANSACTION RELATED MATTERS (1.5).
		2.40	
Total Partner		4.60	
MATTER TOTAL		<u>4.60</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Retention/Fee MatterBill Date: 11/14/22
Bill Number: 1917956

NAME	DATE	HOURS	DESCRIPTION
FITZGERALD P	10/05/22	0.30	REVIEW AND EDIT SUPPLEMENTAL DECLARATION (0.3).
FITZGERALD P	10/15/22	0.20	REVIEW OF FILING (0.2).
FITZGERALD P	10/16/22	0.20	REVIEW OF FILING (0.2).
FITZGERALD P	10/18/22	0.90	ATTENTION TO DECLARATION UPDATE (0.9).
		1.60	
Total Partner		1.60	
CHAN AH	10/12/22	0.30	DRAFT FEE APPLICATION LANGUAGE (0.3).
		0.30	
DEAN B	10/03/22	1.60	REVISE FEE APPLICATION MATERIAL (1.6).
DEAN B	10/10/22	2.10	REVIEW FEE STATEMENT MATERIALS (2.1).
DEAN B	10/12/22	3.50	DRAFT INTERIM FEE APPLICATION (3.5).
DEAN B	10/13/22	1.40	IMPLEMENT REVISIONS TO FEE APPLICATION MATERIALS (1.4).
DEAN B	10/17/22	3.20	IMPLEMENT FINAL REVISIONS TO INTERIM FEE APPLICATION (2.8); CONFER WITH TEAM RE: SAME (0.4).
DEAN B	10/19/22	2.60	REVISE FEE STATEMENT MATERIALS (2.6).
DEAN B	10/27/22	1.80	REVISE FEE STATEMENT MATERIALS (1.8).
		16.20	
MADDEN J	10/03/22	0.60	CONTINUE TO PREPARE DISCLOSURES AND ANALYSIS RE: SAME (0.6).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

MADDEN J	10/04/22	0.90	REVIEW/REVISE AND CONSIDER ISSUES REGARDING DISCLOSURES AND CORRESPONDENCE WITH TEAM RE: SAME (0.9).
MADDEN J	10/12/22	3.50	PREPARE FEE APP MATERIALS AND CORRESPONDENCE WITH TEAM RE: SAME (3.5).
MADDEN J	10/13/22	1.80	PREPARE FEE APP MATERIALS (1.8).
MADDEN J	10/14/22	2.10	REVISE FEE MATERIALS (2.1).
MADDEN J	10/18/22	1.30	CORRESPONDENCE AND ANALYSIS RE: DISCLOSURES (1.3).
		10.20	
O'HARE WS	10/31/22	0.90	PREPARE FEE APPLICATION MATERIALS (0.9).
		0.90	
Total Associate		27.60	
CAMPANA MD	10/06/22	0.30	ASSIST WITH FILING OF THE THIRTY-FOURTH MONTHLY STATEMENT OF SKADDEN FOR COMPENSATION AND REIMBURSEMENT OF EXPENSES, FILED WITH THE U.S. BANKRUPTCY COURT, SOUTHERN DISTRICT OF NEW YORK, CASE NO. 19-23649 (0.3).
CAMPANA MD	10/17/22	1.60	ASSIST WITH FILING OF THE THIRTY-FIFTH MONTHLY FEE STATEMENT AND THE NINTH INTERIM FEE STATEMENT WITH THE U.S. BANKRUPTCY COURT, SOUTHERN DISTRICT OF NEW YORK, CASE NUMBER 19-23649 (1.6).
CAMPANA MD	10/18/22	0.40	REVIEW RECORDS RELATED TO THE BIG QUESTION SURVEY CONDUCTED IN OCTOBER 2019 (0.4).
		2.30	
Total Legal Assistant		2.30	
MATTER TOTAL		<u>31.50</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Various Texas ActionsBill Date: 11/14/22
Bill Number: 1917991

NAME	DATE	HOURS	DESCRIPTION
REDMAN R	10/04/22	0.80	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.5).
REDMAN R	10/07/22	0.80	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.5).
REDMAN R	10/10/22	0.60	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.4).
REDMAN R	10/11/22	0.30	ANALYZE INCOMING FILINGS (0.1); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY(0.2).
REDMAN R	10/14/22	0.60	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS (0.4).
REDMAN R	10/18/22	0.50	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.3).
REDMAN R	10/28/22	1.00	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.7).
REDMAN R	10/31/22	0.90	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS (0.6).
		5.50	
Total Legal Assistant		5.50	
MATTER TOTAL		<u>5.50</u>	